CY1113315T1 - Ιμιδαζολοκαρβοξαμιδια - Google Patents

Ιμιδαζολοκαρβοξαμιδια

Info

Publication number
CY1113315T1
CY1113315T1 CY20121101058T CY121101058T CY1113315T1 CY 1113315 T1 CY1113315 T1 CY 1113315T1 CY 20121101058 T CY20121101058 T CY 20121101058T CY 121101058 T CY121101058 T CY 121101058T CY 1113315 T1 CY1113315 T1 CY 1113315T1
Authority
CY
Cyprus
Prior art keywords
preparation
methods
imidazolocarboxamides
imidazolocarboxamide
anxiety
Prior art date
Application number
CY20121101058T
Other languages
Greek (el)
English (en)
Inventor
Albert Khilevich
Bin Liu
Daniel Ray Mayhugh
Jeffrey Michael Schkeryantz
Deyi Zhang
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113315T1 publication Critical patent/CY1113315T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91Nitro radicals
    • C07D233/92Nitro radicals attached in position 4 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
CY20121101058T 2008-07-18 2012-11-07 Ιμιδαζολοκαρβοξαμιδια CY1113315T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8177408P 2008-07-18 2008-07-18
EP09790351A EP2318375B1 (en) 2008-07-18 2009-07-14 Imidazole carboxamides

Publications (1)

Publication Number Publication Date
CY1113315T1 true CY1113315T1 (el) 2016-04-13

Family

ID=41128155

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101058T CY1113315T1 (el) 2008-07-18 2012-11-07 Ιμιδαζολοκαρβοξαμιδια

Country Status (19)

Country Link
US (1) US7754742B2 (https=)
EP (1) EP2318375B1 (https=)
JP (1) JP5379227B2 (https=)
KR (1) KR101287713B1 (https=)
CN (1) CN102099344B (https=)
AR (1) AR074631A1 (https=)
BR (1) BRPI0915977A2 (https=)
CA (1) CA2731215C (https=)
CY (1) CY1113315T1 (https=)
DK (1) DK2318375T3 (https=)
EA (1) EA018434B1 (https=)
ES (1) ES2393243T3 (https=)
HR (1) HRP20120830T1 (https=)
MX (1) MX2011000611A (https=)
PL (1) PL2318375T3 (https=)
PT (1) PT2318375E (https=)
SI (1) SI2318375T1 (https=)
TW (1) TW201006801A (https=)
WO (1) WO2010009062A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
CN101801930B (zh) 2007-09-14 2013-01-30 奥梅-杨森制药有限公司 1,3-二取代的-4-苯基-1h-吡啶-2-酮
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2681196B1 (en) 2011-03-04 2015-09-09 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
CA2830027C (en) 2011-03-31 2016-04-26 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
MX368391B (es) 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
WO2016169902A1 (en) * 2015-04-23 2016-10-27 F. Hoffmann-La Roche Ag Tetrazole derivatives for use in the treatment of psychiatric disorders
CN104788694B (zh) * 2015-04-29 2018-06-08 江苏亚宝绝缘材料股份有限公司 一种超低收缩率的聚酰亚胺薄膜
WO2017060202A1 (en) 2015-10-06 2017-04-13 F. Hoffmann-La Roche Ag Triazole derivatives
CN108473462B (zh) 2016-02-02 2021-06-22 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑-吡啶衍生物
WO2017202896A1 (en) 2016-05-27 2017-11-30 F. Hoffmann-La Roche Ag Pyrazol compounds as eaat3 inhibitors
JP7068277B2 (ja) 2016-10-14 2022-05-16 エフ.ホフマン-ラ ロシュ アーゲー Eaat3阻害剤としてのイミダゾール化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE7897T1 (de) 1979-09-05 1984-06-15 Glaxo Group Limited Phenol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
US4666928A (en) 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
AU643140B2 (en) 1991-05-31 1993-11-04 Sumitomo Pharmaceuticals Company, Limited Leukotriene B4 antagonist
US6800651B2 (en) 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
AU2003262805A1 (en) 2002-08-26 2004-03-11 Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors
CA2574956A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
US20080312286A1 (en) 2004-07-30 2008-12-18 Pinkerton Anthony B Indanone Potentiators of Metabotropic Glutamate Receptors
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080096935A1 (en) 2004-10-25 2008-04-24 Pinkerton Anthony B Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors
DK1817301T3 (da) * 2004-11-22 2012-02-27 Lilly Co Eli Forstærkere af glutamat-receptorer
JP2008525478A (ja) 2004-12-27 2008-07-17 アストラゼネカ アクチボラグ 神経系及び精神医学系障害の治療のための代謝共役型グルタミン酸受容体アゴニストとしてのピラゾロン化合物
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン

Also Published As

Publication number Publication date
US7754742B2 (en) 2010-07-13
PL2318375T3 (pl) 2013-02-28
KR101287713B1 (ko) 2013-07-23
BRPI0915977A2 (pt) 2018-10-30
JP2011528658A (ja) 2011-11-24
EP2318375B1 (en) 2012-09-19
SI2318375T1 (sl) 2012-11-30
TW201006801A (en) 2010-02-16
AU2009271105A1 (en) 2010-01-21
WO2010009062A1 (en) 2010-01-21
EA201170227A1 (ru) 2011-06-30
AR074631A1 (es) 2011-02-02
ES2393243T3 (es) 2012-12-19
DK2318375T3 (da) 2012-10-08
CN102099344B (zh) 2013-10-30
EP2318375A1 (en) 2011-05-11
EA018434B1 (ru) 2013-07-30
CA2731215A1 (en) 2010-01-21
KR20110022676A (ko) 2011-03-07
CA2731215C (en) 2013-08-27
CN102099344A (zh) 2011-06-15
JP5379227B2 (ja) 2013-12-25
US20100016373A1 (en) 2010-01-21
PT2318375E (pt) 2012-10-22
MX2011000611A (es) 2011-03-01
HRP20120830T1 (hr) 2012-11-30

Similar Documents

Publication Publication Date Title
CY1113315T1 (el) Ιμιδαζολοκαρβοξαμιδια
CY1126518T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1125421T1 (el) Ριβονουκλεϊκα οξεα που περιεχουν ν1-μεθυλο- ψευδοουρακιλες και χρησεις αυτων
CY1123649T1 (el) Παραγωγα ιμιδαζολινης, μεθοδοι παρασκευης αυτων και εφαρμογες αυτων στην ιατρικη
CY1120297T1 (el) Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1120450T1 (el) Διαμορφωτες υποδοχεων οιστρογονων και χρησεις εξ'αυτων
UY32094A (es) Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso.
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
UY32036A (es) Derivados de ciclohexil-amida, composiciones farmacéuticas que los contienen, su preparación y aplicaciones
CY1118680T1 (el) Φαρμακευτικη συνθεση
CL2008000255A1 (es) Compuestos derivados de 2-aminooxazolinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, trastorno bipolar, esquizofrenia, parkinson, alzheimer
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CY1112558T1 (el) Ενωσεις ν-μεθυλαμινομεθυλο ισοϊνδολης και συνθεσεις που τις περιλαμβανουν και μεθοδοι χρησης τους
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
CY1113339T1 (el) Ιμιδαζοκινολινες με ανοσο-ρυθμιστικες ιδιοτητες
CY1112552T1 (el) Υδροξυμεθυλο πυρρολιδινες ως αγωνιστες β3 αδρενεργικου υποδοχεα
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
BR112014010708A2 (pt) pró-fármaco à base de polietilenoglicol de adrenomedulina e utilização do mesmo
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
NI200900042A (es) Nuevo derivados de dismetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.